Literature DB >> 12530032

Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer.

Frederique Spyratos1, Cecile Bouchet, Sengul Tozlu, Marc Labroquere, Sophie Vignaud, Veronique Becette, Rosette Lidereau, Ivan Bieche.   

Abstract

BACKGROUND: The prognostic value of uPA, PAI-1 and PAI-2 mRNA expression was studied in a retrospective series of 130 primary breast cancer patients (median follow-up 8.1 years).
MATERIALS AND METHODS: UPA, PAI-1 and PAI-2 mRNA were quantified by means of real-time quantitative RT-PCR. Comparison with the corresponding protein levels determined by ELISA was performed in 21 cases.
RESULTS: Higher uPA protein values were found in cases with high mRNA values, but the relationship was of borderline significance. PAI-1 and PAI-2 mRNA were positively correlated to protein values. The mRNA expression of uPA, PAI-1 and PAI-2 was significantly correlated with one another. Higher uPA and PAI-1 mRNA values were significantly associated with shorter disease-free survival (DFS) (p = 0.002; p = 0.03, respectively). Low and very high PAI-2 mRNA values tended to be associated with longer DFS. In Cox multivariate analyses, higher uPA and PAI-1 mRNA values were independently associated with shorter DFS. PAI-2 was not retained as a significant variable in the Cox model.
CONCLUSION: These preliminary results indicate that, in breast cancer, uPA, PAI-1 and PAI-2 mRNA analysis by quantitative RT-PCR give results comparable to those obtained at the protein level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530032

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

2.  Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.

Authors:  Mark D Sternlicht; Alison M Dunning; Dan H Moore; Paul D P Pharoah; David G Ginzinger; Koei Chin; Joe W Gray; Frederic M Waldman; Bruce A J Ponder; Zena Werb
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

3.  Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.

Authors:  Isabell D Witzel; Karin Milde-Langosch; Ralph M Wirtz; Claudia Roth; Maike Ihnen; Sven Mahner; Christine Zu Eulenburg; Fritz Jänicke; Volkmar Müller
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

Review 4.  The curability of breast cancer and the treatment of advanced disease.

Authors:  Valentina Guarneri; Pier Franco Conte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-24       Impact factor: 9.236

Review 5.  Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.

Authors:  Niaz Mahmood; Shafaat A Rabbani
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

6.  Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.

Authors:  Matthias Kotzsch; Viktor Magdolen; Thomas Greither; Matthias Kappler; Matthias Bache; Christine Lautenschläger; Susanne Füssel; Alexander W Eckert; Thomas Luther; Gustavo Baretton; Peter Würl; Helge Taubert
Journal:  BMC Cancer       Date:  2011-06-25       Impact factor: 4.430

7.  Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.

Authors:  Philippe Leissner; Thibault Verjat; Thomas Bachelot; Malick Paye; Alexander Krause; Alain Puisieux; Bruno Mougin
Journal:  BMC Cancer       Date:  2006-08-31       Impact factor: 4.430

8.  Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.

Authors:  Keyvan Rezaï; François Lokiec; Isabelle Grandjean; Sophie Weill; Patricia de Cremoux; Vincent Bordier; Richard Ekue; Mickael Garcia; Marie-France Poupon; Didier Decaudin
Journal:  BMC Pharmacol       Date:  2007-10-27

9.  Identification of a three-gene expression signature of poor-prognosis breast carcinoma.

Authors:  Ivan Bièche; Sengül Tozlu; Igor Girault; Rosette Lidereau
Journal:  Mol Cancer       Date:  2004-12-20       Impact factor: 27.401

10.  Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.

Authors:  Omar Al-Janabi; Helge Taubert; Andrea Lohse-Fischer; Michael Fröhner; Sven Wach; Robert Stöhr; Bastian Keck; Max Burger; Wolf Wieland; Kati Erdmann; Manfred P Wirth; Bernd Wullich; Gustavo Baretton; Viktor Magdolen; Matthias Kotzsch; Susanne Füssel
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.